Merus (MRUS)
(Delayed Data from NSDQ)
$49.42 USD
-0.68 (-1.36%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $49.51 +0.09 (0.18%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$49.42 USD
-0.68 (-1.36%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $49.51 +0.09 (0.18%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Zacks News
Strength Seen in Merus N.V. (MRUS): Can Its 37.5% Jump Turn into More Strength?
by Zacks Equity Research
Merus N.V. (MRUS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Merus N.V. (MRUS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Merus N.V. (MRUS) delivered earnings and revenue surprises of -18.33% and 58.06%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Merus N.V. (MRUS) Q2 Earnings Expected to Decline
by Zacks Equity Research
Merus N.V. (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merus N.V. (MRUS) Moves 13% Higher: Will This Strength Last?
by Zacks Equity Research
Merus N.V. (MRUS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Merus N.V. (MRUS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Merus N.V. (MRUS) delivered earnings and revenue surprises of -27.27% and -63.08%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Merus N.V. (MRUS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Merus N.V. (MRUS) delivered earnings and revenue surprises of -26.23% and 11.19%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Merus N.V. (MRUS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Merus N.V. (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lilly (LLY) Inks Deal With Merus to Discover Cancer Antibodies
by Zacks Equity Research
Eli Lilly (LLY) signs a deal with Merus to develop novel T-cell re-directing bispecific antibodies. While Merus will lead early-stage development, Loxo Oncology will take care of further development and commercialization.
Company News for Jan 11, 2021
by Zacks Equity Research
Companies in the news are: CMRX, GSAT, MRUS, FFIV
Merus (MRUS) Stock Up on FDA's Fast Track Tag for Zenocutuzumab
by Zacks Equity Research
The FDA bestows a Fast Track status to Merus' (MRUS) lead pipeline candidate, Zenocutuzumab, for treating metastatic solid tumors harboring NRG1 gene fusions. Shares rise.
Merus (MRUS) Looks Good: Stock Adds 7% in Session
by Zacks Equity Research
Merus (MRUS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Merus NV (MRUS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Merus NV (MRUS) delivered earnings and revenue surprises of -25.93% and -21.76%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Merus N.V. (MRUS) delivered earnings and revenue surprises of 14.89% and 15.78%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Can European Buyouts Aid Canopy Growth's (CGC) Q2 Earnings?
by Zacks Equity Research
Canopy Growth (CGC) acquires a number of European companies to expand its production base across a region that promises great opportunities.
Can Cannabis Therapy Drive Canopy Growth's (CGC) Q2 Earnings?
by Zacks Equity Research
A series of acquisitions is expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal second quarter.
Merus N.V. (MRUS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Merus N.V. (MRUS) delivered earnings and revenue surprises of -5.56% and -27.29%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Acorda (ACOR) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Acorda (ACOR) posts narrower-than-expected loss while revenues top estimates in the second quarter. Inbrija delivers a solid start with sales rising sequentially.
Moving Average Crossover Alert: Merus
by Zacks Equity Research
Merus is looking like an interesting pick from a technical perspective.
NuCana Initiates Dosing in Phase I Study for Solid Tumors
by Zacks Equity Research
NuCana (NCNA) doses the first patient in a phase I study on NUC-7738, which is being evaluated for the treatment of advanced solid tumors.
Will Merus N.V. (MRUS) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Merus N.V. (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moleculin Files New Patents for Cancer Candidate Annamycin
by Zacks Equity Research
Moleculin (MBRX) petitions for new patents to cover annamycin, currently being developed for treating patients with relapsed or refractory acute myeloid leukemia. Shares rise.
Moving Average Crossover Alert: Merus
by Zacks Equity Research
Merus N.V. (MRUS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Inovio Ends Enrollment in Vulvar Dysplasia Study on VGX-3100
by Zacks Equity Research
Inovio (INO) closes enrollment in the phase II study, evaluating VGX-3100 for the treatment of HPV-related vulvar dysplasia.
Nabriva Gets EMA Acceptance for Pneumonia Drug Lefamulin
by Zacks Equity Research
The EMA endorses Nabriva Therapeutics' (NBRV) marketing application for both the intravenous and oral formulations of lefamulin to treat adult patients with community-acquired pneumonia.
Vertex's (VRTX) Symdeko Gets FDA Nod for Use in Children
by Zacks Equity Research
Vertex's (VRTX) Symdeko gets FDA approval to treat underlying cause of cystic fibrosis in children aged 6-11 years with certain mutations in the CFTR gene.